Pancrease HL

Pancreatin

Method of action: Amylolytic, Enzymes, Lipolytic, Proteolytic, Replenishing Deficiency Of Pancreatic Enzymes

Treatment option: Cystic Fibrosis, Pancreatitis, Surgery, Chronic Pancreatitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pancrease HL

What is Pancrease HL?

Pancrease HL is a high-potency pancreatic enzyme replacement therapy. It is designed to assist in the digestion of food for individuals whose bodies do not produce enough digestive enzymes naturally. This condition, known as exocrine pancreatic insufficiency, often occurs when the pancreas is affected by specific medical conditions or surgical procedures.

Composition and Mechanism

The medication contains a mixture of enzymes called pancreatin, which is derived from porcine pancreatic glands. These enzymes include:

Lipase: Responsible for breaking down fats into fatty acids and glycerol.
Amylase: Responsible for breaking down carbohydrates and starches into simple sugars.
Protease: Responsible for breaking down proteins into peptides and amino acids.

Pancrease HL is formulated as gastro-resistant capsules containing enteric-coated minimicrospheres. This specialized coating is designed to protect the enzymes from being inactivated by stomach acid. The spheres are intended to pass through the stomach and release the enzymes in the small intestine, where they can mix with food to facilitate the absorption of nutrients.

Clinical Purpose

The primary role of Pancrease HL is to manage the symptoms of malabsorption. By replacing the missing enzymes, the medication helps the body process fats, proteins, and sugars more effectively. This support is intended to help maintain nutritional balance and prevent complications associated with nutrient deficiencies in patients with impaired pancreatic function.

What side effects are possible with Pancrease HL?

Possible Side Effects and Safety Information

The safety profile of Pancrease HL is formally established through regulatory classifications based on clinical trial data and postmarketing surveillance. Adverse reactions are grouped by incidence and the body systems affected, in line with official governmental documentation.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are often mild and involve the gastrointestinal and nervous systems. In regulatory documents, headache is classified as Very Common. Effects classified as Common typically include abdominal pain and discomfort, nausea, vomiting, flatulence, diarrhea, dizziness, cough, and skin rash.

Serious Adverse Reactions and Safety Constraints

Official labeling describes rare but clinically significant adverse reactions. A severe bowel disorder known as Fibrosing Colonopathy is a serious adverse reaction primarily observed in pediatric patients with Cystic Fibrosis receiving high doses of Pancreatin.

Another safety concern is Hyperuricemia (elevated uric acid), which is associated with the high purine content of the porcine-derived enzymes and is a risk with high-dose use or in patients with pre-existing gout. Hypersensitivity reactions, including allergic responses to porcine proteins, are also documented as a risk.

Safety constraints require that the gastro-resistant coating of the microspheres must not be crushed or chewed, as this can lead to irritation of the oral mucosa.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Pancrease HL focuses on the potential for severe adverse effects associated with chronic, high-dose exposure.

Documented Overdose Presentations

Over-ingestion of the active ingredient, Pancreatin, may lead to documented hyperuricemia, a metabolic disturbance that can present as pain or swelling in the joints. Other documented overdose manifestations include severe diarrhea and vomiting.

The most serious outcome associated with high-dose, prolonged use is the risk of a severe bowel disorder known as fibrosing colonopathy, which can result in colonic stricture. This outcome is specifically noted in the regulatory labeling as a risk particularly for pediatric patients with cystic fibrosis receiving enzyme doses exceeding designated caution thresholds.

Emergency Actions Required

Regulatory guidance mandates that individuals must seek emergency medical attention immediately if an overdose is suspected. Users should call the Poison Control Helpline or emergency services (e.g., 911) if severe symptoms occur, such as trouble breathing or unresponsiveness. Immediate attention is also required for the onset of severe, unusual stomach pain, which may signal the serious bowel disorder.

As treatment is constrained by the official statement that no specific antidote is known, overdose management is officially directed toward symptomatic and supportive treatment of all vital functions.

Therapeutic Uses of Pancrease HL

Quick Facts: Pancrease HL Therapeutic Overview

Condition Treated	Primary Purpose
Exocrine Pancreatic Insufficiency (EPI)	Aids in nutrient assimilation and absorption
EPI related to Cystic Fibrosis	Supports digestion of fats, proteins, and starches
EPI due to Pancreatectomy or Chronic Pancreatitis	Helps maintain nutritional status by assisting with food breakdown

What Pancrease HL Treats: Main Uses and Benefits

Pancrease HL is a prescription medication utilized for individuals with Exocrine Pancreatic Insufficiency (EPI). This condition involves a reduced ability of the pancreas to produce or release the necessary enzymes for proper digestion.

The primary therapeutic goal of this treatment is to help the body process food. It provides support for the digestion of key macronutrients, including fats, proteins, and starches. This process is necessary to facilitate the absorption of these nutrients from the digestive tract, which is fundamental to maintaining nutritional status.

Pancrease HL is used in patients experiencing EPI due to various underlying factors, most commonly Cystic Fibrosis and conditions affecting the pancreas, such as Chronic Pancreatitis or following a Pancreatectomy (surgical removal of the pancreas).

When taken as prescribed, the medication is designed to aid in the breakdown of food to help alleviate symptoms associated with malabsorption, such as excessive fat in the stool (steatorrhea). It serves as a replacement for the digestive enzymes that are not sufficiently produced.

Eligibility and Restrictions for Use

Who Can and Cannot Use Pancrease HL?

Eligibility to use Pancrease HL is defined by regulatory bodies based on specific medical conditions, age, and hypersensitivity status.

Contraindications and Restrictions

Classification	Population/Condition
Absolute Contraindication	Patients with a known hypersensitivity or allergy to proteins of porcine origin or to any component of the medicine.
Conditional Use (Caution)	Patients with Gout, Hyperuricemia, or Renal Impairment must be monitored closely.

Eligibility is established for adult and pediatric patients with Exocrine Pancreatic Insufficiency (EPI), including that associated with Cystic Fibrosis. However, a strict restriction applies to children under 12 years of age with Cystic Fibrosis: use is cautioned at high doses (over 6,000 lipase units/kg/meal) due to the risk of Fibrosing Colonopathy. Regarding reproductive status, use is conditional during pregnancy and generally allowed during breastfeeding, reflecting the negligible systemic absorption of the enzyme.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Pancrease HL is primarily defined by its non-systemic, local action within the gastrointestinal tract and its specialized gastro-resistant formulation, according to official regulatory documents.

Documented Drug Interactions

Interacting Substance/Class	Official Interaction Outcome
Carbohydrate Absorption Inhibitors (e.g., Acarbose, Miglitol)	May reduce the therapeutic effect of the inhibitor through functional antagonism.
Antacids (e.g., Calcium/Magnesium Hydroxide)	May reduce the efficacy of Pancrease HL by interfering with the gastro-resistant coating.
Gastric Acid Reducers (e.g., Cimetidine)	May potentiate the effect of Pancrease HL by protecting the enzymes from premature acid degradation.
Micronutrients (Iron, Folic Acid)	May diminish the systemic absorption of these nutrients with co-administration.

Mechanism of Action

The Pancrease HL formulation contains lipases, proteases, and amylases which function to hydrolyze dietary fats, proteins, and starches, respectively, within the intestinal lumen. This enzymatic hydrolysis yields smaller molecules (monoglycerides, free fatty acids, oligopeptides, amino acids, and monosaccharides) facilitating their subsequent transport across the intestinal epithelium.

The enteric coating on the enzyme microspheres protects the active components from gastric acid-mediated denaturation within the stomach. Upon reaching the higher pH environment of the duodenum and jejunum, the coating dissolves, releasing the active pancreatic enzymes into the intestinal chyme. The specific pH-sensitive polymer composition of the coating determines the site and rate of enzyme release.

Dosage and Administration Information

Pancrease HL is a prescription medication administered orally and is intended for use as a long-term replacement therapy. The core principle of administration requires that the medicine be taken with every meal and snack to ensure the enzymes are present when food enters the digestive tract.

Dosing Protocol

The dosage is highly individualized and is determined by the patient’s body weight and the degree of malabsorption. For adults and children aged four years and older, the official initial starting dose is 500 lipase units per kilogram of body weight per meal. The dose taken with a snack is typically half of the dose taken with a full meal. Dosing is subject to strict limits and must not exceed 10,000 lipase units per kilogram of body weight per day.

Administration and Special Handling

The gastro-resistant capsules must be swallowed whole with sufficient liquids. It is a critical procedural constraint that the capsule or its contents are not crushed or chewed, as this action compromises the enteric coating and deactivates the enzymes before they reach the small intestine. If a patient is unable to swallow the capsule, the contents may be sprinkled onto a small amount of acidic soft food (pH 4.5 or less), such as applesauce, and the mixture must be consumed immediately.

Population Considerations

Official guidelines include specific starting dose adjustments for pediatric patients. For instance, children between 12 months and four years of age typically begin therapy at 1,000 lipase units per kilogram of body weight per meal.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides a neutral overview of the research and clinical studies involving Pancrease HL (Pancrelipase). It describes what the studies evaluated and measured, rather than providing interpretation or clinical recommendations.

Initial Efficacy Studies

Studies investigated the drug’s role in managing Exocrine Pancreatic Insufficiency (EPI), a condition often associated with cystic fibrosis or chronic pancreatitis. Research evaluated the drug’s influence on key digestive markers, such as the Coefficient of Fat Absorption (CFA) and the Coefficient of Nitrogen Absorption (CNA), when compared against a placebo.

In clinical trials, Pancrease HL (a high-strength pancrelipase formulation) was associated with statistically significant increases in CFA and CNA values in adult participants with EPI. Improvements were also measured in participant-reported gastrointestinal symptoms, including reductions in stool frequency, stool weight, and abdominal pain.

Long-term Outcomes and Tolerability

Patient Population and Nutritional Status

The clinical data largely focus on the drug's use in individuals with EPI due to chronic pancreatitis or cystic fibrosis. Studies evaluated whether the drug was associated with improvements in nutritional markers, including changes in body weight and body mass index (BMI) over treatment periods, often spanning six months or longer.

Safety Profile

Clinical trials collect data on the drug’s tolerability profile in adult and pediatric participants. Information about the drug's tolerability profile and patient outcomes is available for review by qualified healthcare professionals. Adverse events reported during trials were predominantly related to the gastrointestinal tract.

Specific Symptom and Disease Activity Research

Research has explored whether the medication is associated with changes in the frequency of disease flare-ups and assessed participant-reported relief over time. Ongoing research continues to assess the long-term impact on nutritional status and overall quality of life.

Frequently Asked Questions (FAQ)

Common questions about Pancrease HL (FAQ)

Q: Is Pancrease HL the same as other medicines for the same condition?

Pancrease HL belongs to a category of medications known as pancreatic enzyme replacement therapy, or PERT. Official regulatory documents confirm that, like other approved PERT products, it contains the three key enzymes: lipase, protease, and amylase.

Q: Are there different strengths or versions of Pancrease HL available?

Yes, official product information from regulatory bodies indicates that pancrelipase medications are available in different strengths. These strengths typically vary based on the number of lipase units contained in each capsule.

Q: What is the most frequently reported side effect of Pancrease HL?

Official regulatory documents classify adverse reactions based on how often they occurred in clinical trials. Headache is often classified as a Very Common effect, meaning it was reported in 10% or more of participants in studies.

Q: Does alcohol consumption affect how Pancrease HL works?

Official warnings and restrictions mention that the use of heavy alcohol is a documented restriction that should be discussed in the context of the underlying condition. Regulatory warnings advise against concomitant heavy alcohol use.

Q: Is Pancrease HL meant to be taken indefinitely?

Regulatory guidance and official records frequently describe the medicine’s use as long-term replacement therapy for chronic conditions. The duration of use is generally determined based on the patient's ongoing need for enzyme support.

Q: Does Pancrease HL need to be refrigerated?

No, official product information specifies storage below 25 C (77 F). The instructions are generally to keep the product in a cool, dry place and to avoid refrigeration, as per official storage guidelines.

Q: Is it true that Pancrease HL is used for conditions other than its main approved use?

The officially approved indications for Pancrease HL are specific, listing conditions like exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis or chronic pancreatitis. Official documents only describe and approve the indications related to EPI for this product.

Q: What is the duration of action for a single dose of Pancrease HL?

Official product information emphasizes that the medicine must be taken with every meal and snack. This is because the enzyme release is designed to coincide with the time food is passing through the small intestine, ensuring enzyme presence throughout the digestive process.

Q: Can Pancrease HL interact with common over-the-counter pain relievers?

Regulatory documents list documented interactions with medications that affect stomach acid, like some antacids and gastric acid reducers. Common pain relievers are not among the specific drug-to-drug interactions that are required to be documented in the official labeling.

Q: How quickly should someone notice effects from Pancrease HL?

Clinical trials evaluate the medicine’s efficacy based on objective markers, such as the improvement in fat absorption, which are typically measured within the first week of treatment. Patient-reported improvements in gastrointestinal symptoms have been noted during the initial periods of clinical trials.

Q: Is it normal to feel bloated when starting Pancrease HL?

Official safety information lists common gastrointestinal effects, including abdominal pain and flatulence (passing gas). These are classified as common adverse reactions that a person may experience when initiating therapy.

Q: Can older adults use Pancrease HL safely?

Official labels generally indicate that the overall guidance established for adult patients applies. Specific data regarding different responses in older adults compared to younger patients is limited in the available clinical trials.

Q: What happens if a dose of Pancrease HL is missed?

Official patient instructions advise that if a dose is forgotten, it should be skipped. The patient should then wait for the next scheduled meal or snack to take the usual dose with food.

Q: Does the time of day matter when taking Pancrease HL?

Official instructions specify that the medicine must be taken with every meal and snack. The most critical timing factor is the presence of food in the digestive tract to ensure the enzymes are released at the proper moment.

Q: How is the safety of Pancrease HL monitored by health authorities?

Health authorities actively monitor the medicine's safety profile through structured systems like postmarketing surveillance. This mechanism is how warnings for rare, but serious, adverse reactions—such as fibrosing colonopathy—are documented and added to official product information.

Q: What is the research evidence for Pancrease HL based on?

The official evidence supporting the medicine's use is primarily based on randomized, double-blind, placebo-controlled trials. These are studies where the drug's effect is scientifically compared against an inactive substance (a placebo) to measure efficacy on key markers.

Q: Is Pancrease HL a type of steroid or hormone?

No, official product descriptions clearly classify Pancrease HL as a digestive enzyme supplement derived from porcine (pig) extracts. Hormones and steroids belong to entirely different classes of pharmaceutical products.

Q: How does Pancrease HL compare to dietary enzyme supplements?

Pancrease HL is a prescription pharmaceutical preparation with standardized levels of active enzymes and is tightly regulated by government agencies. Dietary enzyme supplements are generally classified under different regulatory pathways than prescription pharmaceutical preparations like Pancrease HL.

Q: Are there different patient eligibility criteria for Pancrease HL in different countries?

Yes, official notices from international regulatory bodies address variations in product availability, specific formulations, or administrative requirements that can vary based on local market factors. This can influence the details of eligibility in different regions.

Q: Is Pancrease HL a controlled substance?

No, regulatory authorities classify Pancrease HL as a digestive enzyme product. It is not listed on any federal or international controlled substances schedules.

Q: What does the term 'non-directive' mean in the context of official drug information for Pancrease HL?

The term 'non-directive' refers to the regulatory requirement that official drug labeling must use language that describes verifiable facts, evidence, and risks. This means the information avoids giving personalized advice or recommendations for a patient to take a specific action.

How should Pancrease HL be stored and disposed of?

The official regulatory labeling for Pancrease HL defines specific environmental and container controls to protect the active enzymes from degradation.

Official Storage Conditions

Requirement	Constraint
Temperature	Store below 25 C (77 F).
Container Integrity	Keep in the original container and keep the bottle tightly closed.
Environmental Protection	Protect the capsules from moisture and light.

Stability and Disposal

The product must be stored out of the sight and reach of children. Once the original container is opened, the medicine has a limited in-use shelf-life, often specified as 3 to 6 months, after which any remaining medicine must be discarded. Disposal of unused or expired Pancrease HL must be carried out according to local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.